Summary
56 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 15 USD is left as free cash.
- It passes 8 of the 9 points of the Piotroski financial health test.
What to watch
- Repaying its net debt would take 4.3 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedToday you pay 25.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.9% a year over the last 3 years. For the next fiscal year analysts expect revenue to grow by 8.6%. Earnings per share fell by 0.5% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 71 USD
- Sales and administration 13 USD
- Taxes and other 7.7 USD
- Net profit 8.7 USD
Net profit, industry median (Medical - Care Facilities) 6.7 USD
Out of every 100 USD of revenue, 8.7 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.63%
- Paid out of profit
- 16%
You receive $0.25 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $40 is at today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.